CAMBRIDGE, Mass.--(BUSINESS WIRE)--GENOMETRY, INC. today announced entering into a service agreement with JANSSEN PHARMACEUTICA NV of Beerse, Belgium under the terms of which Genometry will generate gene-expression profiles from 250,000 compounds from Janssen’s small-molecule screening library using its proprietary L1000™ Expression Profiling technology. This is the first time gene-expression profiling has been applied at this scale, and this multi-year contract showcases a commitment to high-throughput gene-expression profiling for multiple drug discovery and development applications. The data will be used for primary screening and library characterization as well as to improve the selection of candidate drugs prior to clinical studies.
“L1000 was developed to make gene-expression profiling experiments of unprecedented scale and scope possible, and Genometry was founded to get this transformative technology into the hands of professional drug developers,” said Justin Lamb, Ph.D., Genometry’s President and CEO. “We are therefore thrilled to see Janssen engage in a true library-scale profiling effort uniquely enabled by Genometry’s capabilities.”
GENOMETRY, INC. is a life-science platform-technology company commercializing and popularizing a revolutionary high-throughput gene-expression profiling method for next-generation pharmaceutical discovery applications. L1000™ Expression Profiling produces gene-expression profiles at a rate of thousands a day and at only a fraction of the cost of conventional methods, enabling the use of expression profiling at a scale never before possible. GENOMETRY, INC. is the sole and exclusive provider of commercial gene-expression profiling services using L1000, and offers data-generation solutions and tailored expert support to the pharmaceutical, biotechnology, personal care, and consumer products industries from headquarters in Kendall Square, Cambridge MA and satellite facilities worldwide. More information is available at www.genometry.com or from email@example.com.